Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

February 4, 2021 4 February, 2021

Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany

February 4, 2021 9:00 a.m. EST

LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce the start of trading of Sernova shares on Xetra, the electronic trading system of Deutsche Börse AG in Germany (German Securities Identification Number (WKN): A0LBCR, International Securities Identification Number (ISIN): CA81732W1041, German Ticker-Symbol: PSH).

Xetra is an electronic trading platform operated by the Frankfurt Stock Exchange. It offers trading in stocks, funds, bonds, warrants, and commodities contracts. Launched in 1997, the majority of stock market transactions in Germany are through the Xetra trading venue: approximately 90 percent of all trading in shares across all German exchanges is now conducted through Xetra making it the largest of Germany’s stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and Hong Kong are connected via Xetra servers.

Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities are executed swiftly and at prices in line with the market. Moreover, this principle is supported by Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure additional liquidity and fair prices, making it the first choice for institutional investors. mwb Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of Sernova’s shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.

mwb fairtrade Wertpapierhandelsbank AG ( is a securities service provider licensed by the German Federal Financial Supervisory Authority (BaFin) with branches near Munich, Hamburg, Hanover, Frankfurt as well as Berlin. Founded in 1993 and active in two business divisions: Securities Trading and Corporates & Markets, mwb manages approximately 40,000 order books for German and international securities as well as 89 Designated Sponsors mandates making mwb one of the largest order book managers in Germany.

“mwb has developed in-depth knowledge on enabling Xetra trading for overseas companies. We are happy to support Sernova with the rollout of their exciting equity story and look forward to enhance Euro-based trading possibilities for their institutional and retail investor base in Europe,” said Sascha Guenon, Head of Designated Sponsoring and Corporate Broking at mwb.

“We are experiencing a significant increase of interest from institutional investors in Europe, especially in German-speaking countries, and want to provide them with a more efficient way to trade our shares," commented Dr. Philip Toleikis, President and CEO of Sernova. "This is an important step to increase the percentage of long-term oriented institutional investors within our group of shareholders who understand the potential of our innovative platform technologies in the regenerative medicine field as well as the valuation gap with our competitors. mwb has a strong network of biotech investors and we are looking forward to presenting the potential of Sernova’s regenerative medicine platform to them.”


Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126


This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.